PL3658552T3 - Sposób wytwarzania n-(5-((4-(4-((dimetyloamino)metylo)-3-fenylo-1h-pirazol-1-ilo)pirymidyn-2-ylo)amino)-4-metoksy-2-morfolinofenylo)akrylamidu przez poddanie reakcji odpowiedniej aminy z chlorkiem 3-halogenopropionylu - Google Patents

Sposób wytwarzania n-(5-((4-(4-((dimetyloamino)metylo)-3-fenylo-1h-pirazol-1-ilo)pirymidyn-2-ylo)amino)-4-metoksy-2-morfolinofenylo)akrylamidu przez poddanie reakcji odpowiedniej aminy z chlorkiem 3-halogenopropionylu

Info

Publication number
PL3658552T3
PL3658552T3 PL18837360.9T PL18837360T PL3658552T3 PL 3658552 T3 PL3658552 T3 PL 3658552T3 PL 18837360 T PL18837360 T PL 18837360T PL 3658552 T3 PL3658552 T3 PL 3658552T3
Authority
PL
Poland
Prior art keywords
morpholinophenyl
pyrazol
pyrimidin
acrylamide
dimethylamino
Prior art date
Application number
PL18837360.9T
Other languages
English (en)
Inventor
Sang-Ho Oh
Ja-Heouk Khoo
Jong-Chul Lim
Seong-Ran LEE
Hyun Ju
Woo-Seob Shin
Dae-Gyu Park
Su-Min Park
Yoon-Ah HWANG
Original Assignee
Yuhan Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3658552(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corporation filed Critical Yuhan Corporation
Publication of PL3658552T3 publication Critical patent/PL3658552T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2284—Compounds with one or more Sn-N linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
PL18837360.9T 2017-07-28 2018-07-25 Sposób wytwarzania n-(5-((4-(4-((dimetyloamino)metylo)-3-fenylo-1h-pirazol-1-ilo)pirymidyn-2-ylo)amino)-4-metoksy-2-morfolinofenylo)akrylamidu przez poddanie reakcji odpowiedniej aminy z chlorkiem 3-halogenopropionylu PL3658552T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (en) 2017-07-28 2018-07-25 IMPROVED PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
PL3658552T3 true PL3658552T3 (pl) 2024-02-19

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18837360.9T PL3658552T3 (pl) 2017-07-28 2018-07-25 Sposób wytwarzania n-(5-((4-(4-((dimetyloamino)metylo)-3-fenylo-1h-pirazol-1-ilo)pirymidyn-2-ylo)amino)-4-metoksy-2-morfolinofenylo)akrylamidu przez poddanie reakcji odpowiedniej aminy z chlorkiem 3-halogenopropionylu

Country Status (32)

Country Link
US (4) US10889578B2 (pl)
EP (1) EP3658552B1 (pl)
JP (2) JP7228562B2 (pl)
KR (1) KR102688084B1 (pl)
CN (2) CN111315742B (pl)
AU (2) AU2018308038B2 (pl)
BR (1) BR112020001278A2 (pl)
CA (1) CA3070069C (pl)
CO (1) CO2020000374A2 (pl)
DK (1) DK3658552T3 (pl)
EA (1) EA202090383A1 (pl)
ES (1) ES2962961T3 (pl)
FI (1) FI3658552T3 (pl)
HR (1) HRP20231191T1 (pl)
HU (1) HUE063533T2 (pl)
IL (2) IL271973B (pl)
LT (1) LT3658552T (pl)
MA (1) MA49700B1 (pl)
MD (1) MD3658552T2 (pl)
MX (2) MX2022008743A (pl)
MY (1) MY198379A (pl)
PH (1) PH12020500059A1 (pl)
PL (1) PL3658552T3 (pl)
PT (1) PT3658552T (pl)
RS (1) RS64654B1 (pl)
SA (2) SA522431428B1 (pl)
SG (1) SG11201913517UA (pl)
SI (1) SI3658552T1 (pl)
SM (1) SMT202300339T1 (pl)
UA (1) UA125317C2 (pl)
WO (1) WO2019022485A1 (pl)
ZA (1) ZA202001250B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL271973B (en) 2017-07-28 2022-08-01 Yuhan Corp An improved process for the preparation of aminopyrimidine derivatives
PH12021552798A1 (en) 2019-05-14 2022-09-19 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
EP4135669A1 (en) 2020-04-14 2023-02-22 Janssen Biotech, Inc. Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof
CN116199701A (zh) * 2023-02-27 2023-06-02 安徽中医药大学 一种基于分子内自由基环加成制备吡唑并恶嗪草酮类化合物及其制备方法
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
AU2024337472A1 (en) 2023-09-05 2026-04-16 Janssen Biotech, Inc. Methods of treating non-small cell lung cancer
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
IL161921A0 (en) 2001-11-27 2005-11-20 Wyeth Corp 3-Cyanoquinolines as inhibitors of egf-r and her2 kinases
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
ES2555803T3 (es) 2006-10-23 2016-01-08 Cephalon, Inc. Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CN102791697A (zh) 2009-10-12 2012-11-21 瑞科西有限公司 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物
US8629132B2 (en) * 2009-11-13 2014-01-14 Genosco Kinase inhibitors
RU2607453C2 (ru) 2009-12-04 2017-01-10 Сенхва Байосайенсиз, Инк. Пиразолопиримидины и родственные гетероциклы как ск2 ингибиторы
ES2616238T3 (es) 2010-10-06 2017-06-12 Glaxosmithkline Llc, Corporation Service Company Derivados de bencimidazol como inhibidores de PI3 quinasa
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
RU2591195C2 (ru) 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Замещенные n-(1h-индазол-4-ил) имидазол [1,2-а]пиридин-3- карбоксамидные соединения в качестве ингибиторов рецепторной тирозинкиназы iii типа
MY161925A (en) 2011-07-27 2017-05-15 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
UY34539A (es) 2011-12-23 2013-06-28 Millennium Pharm Inc Heteroarilos y usos de los mismos
USRE47451E1 (en) 2011-12-30 2019-06-25 Hanmi Pharm. Co. Ltd. Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
JP6468611B2 (ja) 2014-05-13 2019-02-13 アリアド ファーマシューティカルズ， インコーポレイテッド キナーゼ阻害のためのヘテロアリール化合物
CN106660993B (zh) 2014-06-12 2020-09-11 上海复尚慧创医药研究有限公司 一类激酶抑制剂
NZ730012A (en) * 2014-10-13 2019-06-28 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
CN104788427B (zh) * 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
AR111469A1 (es) 2017-04-21 2019-07-17 Yuhan Corp Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
IL271973B (en) 2017-07-28 2022-08-01 Yuhan Corp An improved process for the preparation of aminopyrimidine derivatives
PL3658553T3 (pl) 2017-07-28 2022-10-10 Yuhan Corporation Związki pośrednie przydatne do syntezy pochodnych aminopirymidyny, sposób ich wytwarzania oraz sposób wytwarzania pochodnych aminopirymidyny z ich zastosowaniem
JP7189932B2 (ja) 2017-07-28 2022-12-14 ユハン コーポレーション タンパク質キナーゼに対する選択的阻害剤の合成に有用な中間体及びそれを調製するためのプロセス
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
CA3070069A1 (en) 2019-01-31
HUE063533T2 (hu) 2024-01-28
UA125317C2 (uk) 2022-02-16
RS64654B1 (sr) 2023-10-31
JP2020528440A (ja) 2020-09-24
US20230312545A1 (en) 2023-10-05
JP7228562B2 (ja) 2023-02-24
MD3658552T2 (ro) 2024-02-29
PT3658552T (pt) 2023-11-03
CN111315742B (zh) 2023-09-01
IL271973A (en) 2020-02-27
AU2022202936B2 (en) 2023-04-27
US20200165236A1 (en) 2020-05-28
US11708362B2 (en) 2023-07-25
CA3070069C (en) 2024-02-20
MA49700B1 (fr) 2023-09-27
CO2020000374A2 (es) 2020-05-05
EA202090383A1 (ru) 2020-06-15
SI3658552T1 (sl) 2023-11-30
KR102688084B1 (ko) 2024-07-24
US20220281861A1 (en) 2022-09-08
SA522431428B1 (ar) 2024-10-21
WO2019022485A1 (en) 2019-01-31
ZA202001250B (en) 2023-04-26
JP7539451B2 (ja) 2024-08-23
CN111315742A (zh) 2020-06-19
KR20190013553A (ko) 2019-02-11
US20210269427A1 (en) 2021-09-02
MY198379A (en) 2023-08-28
NZ761156A (en) 2024-01-26
MA49700A (fr) 2021-03-17
SG11201913517UA (en) 2020-02-27
AU2018308038A1 (en) 2020-01-30
EP3658552B1 (en) 2023-09-13
CN116987112B (zh) 2025-12-19
US10889578B2 (en) 2021-01-12
FI3658552T3 (fi) 2023-11-16
BR112020001278A2 (pt) 2020-07-21
EP3658552A4 (en) 2021-06-23
ES2962961T3 (es) 2024-03-22
EP3658552A1 (en) 2020-06-03
MX393995B (es) 2025-03-24
IL271973B (en) 2022-08-01
MX2022008743A (es) 2023-02-02
DK3658552T3 (da) 2023-11-20
IL292429B2 (en) 2023-09-01
US12187714B2 (en) 2025-01-07
LT3658552T (lt) 2023-11-27
JP2023027091A (ja) 2023-03-01
CN116987112A (zh) 2023-11-03
IL292429A (en) 2022-06-01
PH12020500059A1 (en) 2020-09-28
US11286253B2 (en) 2022-03-29
AU2022202936A1 (en) 2022-05-26
AU2018308038B2 (en) 2022-02-03
HRP20231191T1 (hr) 2024-02-02
IL292429B1 (en) 2023-05-01
SA520411112B1 (ar) 2022-02-21
SMT202300339T1 (it) 2023-11-13

Similar Documents

Publication Publication Date Title
SI3658552T1 (sl) Postopek za pripravo N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il )amino)-4-metoksi-2-morfolinofenil)akrilamida z reagiranjem ustreznega amina s 3-halo-propionil kloridom
HUS2400025I1 (hu) N-(ciano-metil)-4-(2-(4-morfolino-fenil-amino)-4-pirimidinil)-benzamid hidroklorid sók
PH12018502136A1 (en) Heterocyclic amides useful as protein modulators
IL263739B (en) History of n-(converted-phenyl)-sulfonamide as kinase inhibitors
SI3658547T1 (sl) Postopek za pripravo n-(5-(4-(4-formil-3-fenil-1h-pirazol-1-1l)pirimidin-2-ilamino)-4-metoksi -2-morfolinofenil)akrilamida
SI3164385T1 (sl) Nova polimorfna oblika N-(2-(6-fluoro-LH-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoksi) benzilamin hidroklorida za zdravljenje Alzheimerjeve bolezni
PL3153022T3 (pl) N-(3’,4’-dichloro-5-metoksybifenyl-2-ylo)-3-(difluorometylo)-1-metylo-1H-pirazolo-4-karboksyamid
LT3334707T (lt) N-(3,5-dimetilfenil)-n'-(2-trifluormetilfenilo) guanidino paruošimo būdas